Effects of COVID-19 vaccine type on Guillain-Barré syndrome: Two cases and a literature review

Guillain-Barré syndrome (GBS) is a rare but severe complication of COVID-19 vaccination. We report two cases of GBS following vaccination with the adenovirus vector vaccine ChAdOx1 nCoV-19 (Vaxzevria, AstraZeneca) and review the relevant literature. Relevant studies published between December 2020 a...

Full description

Saved in:
Bibliographic Details
Published inHuman vaccines & immunotherapeutics Vol. 19; no. 1; p. 2171231
Main Authors Lee, Hsin-Yu, Lien, Wan-Ching
Format Journal Article
LanguageEnglish
Published United States Taylor & Francis 31.12.2023
Taylor & Francis Group
Subjects
Case Report
ChAdOx1 nCoV-19
Coronavirus – Case Report
COVID-19 - complications
COVID-19 - prevention & control
covid-19 vaccine
COVID-19 Vaccines - adverse effects
Guillain-Barre Syndrome - epidemiology
Guillain-Barre Syndrome - etiology
guillain-barré syndrome
Humans
Influenza Vaccines
Vaccination - adverse effects
COVID-19 vaccine
Guillain-Barré syndrome
Online AccessGet full text

Cover

More Information
Summary:Guillain-Barré syndrome (GBS) is a rare but severe complication of COVID-19 vaccination. We report two cases of GBS following vaccination with the adenovirus vector vaccine ChAdOx1 nCoV-19 (Vaxzevria, AstraZeneca) and review the relevant literature. Relevant studies published between December 2020 and May 2022 including 881 patients with GBS were reviewed. GBS incidence and the need for mechanical ventilation were reported at a higher level among patients receiving Vaxzevria (n = 400). However, incidence cannot be accurately estimated from case reports. Thus, the true GBS rates following COVID-19 vaccination should be determined by population-based data.
Bibliography:ObjectType-Case Study-2
SourceType-Scholarly Journals-1
ObjectType-Review-3
content type line 23
ObjectType-Feature-5
ObjectType-Article-4
ObjectType-Report-1
ISSN:2164-5515
2164-554X
DOI:10.1080/21645515.2023.2171231